Sight Sciences Ownership

SGHT Stock  USD 2.97  0.08  2.62%   
Sight Sciences shows a total of 50.4 Million outstanding shares. Over half of Sight Sciences' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Dividend Paid And Capex Coverage Ratio is likely to drop to -72.03 in 2025. Common Stock Shares Outstanding is likely to drop to about 49.4 M in 2025. Net Loss is likely to gain to about (73.7 M) in 2025.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sight Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
For more information on how to buy Sight Stock please use our How to Invest in Sight Sciences guide.

Sight Stock Ownership Analysis

About 20.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.62. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sight Sciences recorded a loss per share of 1.01. The entity had not issued any dividends in recent years. Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company was incorporated in 2010 and is headquartered in Menlo Park, California. Sight Sciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 212 people. To find out more about Sight Sciences contact the company at 877 266 1144 or learn more at https://www.sightsciences.com.
Besides selling stocks to institutional investors, Sight Sciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Sight Sciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Sight Sciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Sight Sciences Quarterly Liabilities And Stockholders Equity

143.6 Million

Sight Sciences Insider Trades History

About 20.0% of Sight Sciences are currently held by insiders. Unlike Sight Sciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Sight Sciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Sight Sciences' insider trades
 
Covid

Sight Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Sight Sciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sight Sciences backward and forwards among themselves. Sight Sciences' institutional investor refers to the entity that pools money to purchase Sight Sciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Prosight Management, Lp2024-09-30
531.2 K
Northern Trust Corp2024-09-30
325.8 K
D. E. Shaw & Co Lp2024-09-30
321.6 K
Charles Schwab Investment Management Inc2024-09-30
257 K
Morgan Stanley - Brokerage Accounts2024-09-30
223.9 K
Jacobs Levy Equity Management, Inc.2024-09-30
207.9 K
National Asset Management Inc2024-09-30
195.1 K
Panagora Asset Management Inc2024-09-30
194.8 K
Millrace Asset Group, Inc2024-09-30
138.8 K
Kck Ltd2024-12-31
4.4 M
Ubs Group Ag2024-09-30
2.5 M
Note, although Sight Sciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Sight Sciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sight Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sight Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sight Sciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Jeremy Hayden six days ago
Disposition of 6922 shares by Jeremy Hayden of Sight Sciences at 2.781 subject to Rule 16b-3
 
Badawi David over a week ago
Disposition of 5423 shares by Badawi David of Sight Sciences at 2.781 subject to Rule 16b-3
 
Paul Badawi over a week ago
Disposition of 24819 shares by Paul Badawi of Sight Sciences at 2.924 subject to Rule 16b-3
 
Badawi David over two weeks ago
Disposition of 3829 shares by Badawi David of Sight Sciences at 3.259 subject to Rule 16b-3
 
Alison Bauerlein over three weeks ago
Disposition of 10102 shares by Alison Bauerlein of Sight Sciences at 3.522 subject to Rule 16b-3
 
Paul Badawi over three weeks ago
Disposition of 12236 shares by Paul Badawi of Sight Sciences at 3.597 subject to Rule 16b-3
 
Encrantz Staffan over a month ago
Acquisition by Encrantz Staffan of 126664 shares of Sight Sciences at 2.1892 subject to Rule 16b-3
 
Manohar Raheja over a month ago
Acquisition by Manohar Raheja of 3376 shares of Sight Sciences at 3.89 subject to Rule 16b-3
 
Manohar Raheja over two months ago
Acquisition by Manohar Raheja of 4624 shares of Sight Sciences at 3.988 subject to Rule 16b-3
 
Jesse Selnick over two months ago
Disposition of 2891 shares by Jesse Selnick of Sight Sciences at 12.379 subject to Rule 16b-3
 
Encrantz Staffan over two months ago
Disposition of 551802 shares by Encrantz Staffan of Sight Sciences at 3.73 subject to Rule 16b-3
 
Manohar Raheja over two months ago
Acquisition by Manohar Raheja of 96000 shares of Sight Sciences at 4.59 subject to Rule 16b-3

Sight Sciences Outstanding Bonds

Sight Sciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Sight Sciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Sight bonds can be classified according to their maturity, which is the date when Sight Sciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Sight Sciences Corporate Filings

8K
28th of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
23rd of January 2025
Other Reports
ViewVerify
F4
21st of January 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
13A
14th of November 2024
An amended filing to the original Schedule 13G
ViewVerify

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Sight Stock Analysis

When running Sight Sciences' price analysis, check to measure Sight Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sight Sciences is operating at the current time. Most of Sight Sciences' value examination focuses on studying past and present price action to predict the probability of Sight Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sight Sciences' price. Additionally, you may evaluate how the addition of Sight Sciences to your portfolios can decrease your overall portfolio volatility.